Black Diamond Therapeutics, Inc.
139 Main Street, Suite 301
Cambridge
MA
02142
United States
Website: http://www.blackdiamondtherapeutics.com/
Email: info@bdtherapeutics.com
About Black Diamond Therapeutics, Inc.
Our Vision
Precision Cancer Medicines for Every Genetically-Defined Patient
Company Overview
Black Diamond Therapeutics: A Next-Wave Cancer Precision Medicine Company
Black Diamond Therapeutics has pioneered the development of selective medicines for patients with genetically-defined cancers driven by oncogenes activated by allosteric mutations.
The cornerstone of our approach derives from evolving trends in cancer clinical medicine. Genome-wide information – now routinely obtained from DNA testing of cancer patients – identifies clusters of uncharacterized genomic alterations. Today, new baskets of un-drugged oncogenic targets exist, leading to the identification of additional cancer patients in need of novel therapies.
Using our MAP platform, Black Diamond Therapeutics is pioneering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets, and to develop novel approaches to creating highly selective therapeutics.
57 articles with Black Diamond Therapeutics, Inc.
-
Black Diamond Therapeutics to Present at Upcoming Investor Conferences - Nov 08, 2021
11/8/2021
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the following upcoming investor conferences.
-
Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/8/2021
Black Diamond Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
-
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR Programs at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/8/2021
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, announced the presentation of preclinical data for three early-stage pipeline programs in oral and poster sessions at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics.
-
Diamond Therapeutics Appoints Renowned Psychiatrist and Author Dr. Torsten Passie to Scientific Advisory Board
10/5/2021
Diamond Therapeutics Inc. is pleased to announce the appointment of Dr. Torsten Passie to its scientific advisory board.
-
Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-1535, BRAF, and FGFR Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9/30/2021
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced the presentation of pre-clinical data for three pipeline programs in oral and poster sessions at the upcoming AACR-NCI-EORTC Virtual International Conference.
-
Black Diamond Therapeutics to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
9/21/2021
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 4:40 PM ET.
-
Black Diamond Therapeutics and OpenEye Scientific Announce Collaboration to Expand MAP Drug Discovery Platform
9/21/2021
Black Diamond Therapeutics and OpenEye Scientific announced that they are entering into a strategic partnership incorporating OpenEye’s Orion® molecular design platform into Black Diamond’s proprietary Mutation-Allostery-Pharmacology drug discovery engine to advance Black Diamond’s efforts to develop MasterKey inhibitor cancer therapies.
-
Black Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
8/12/2021
Black Diamond Therapeutics, Inc. today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
-
Black Diamond Therapeutics Announces Appointment of Mark Velleca, M.D., Ph.D. to Board of Directors
8/10/2021
Black Diamond Therapeutics, Inc. today announced the appointment of Mark A. Velleca, M.D., Ph.D. to its Board of Directors.
-
Black Diamond Therapeutics to Present at Upcoming Investor Conferences - Aug 04, 2021
8/4/2021
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an update about the Company’s progress at the following upcoming investor conferences
-
Diamond Therapeutics Hires Industry Veteran David Brown, PhD, to Further Advance Formulation of Psilocybin
7/26/2021
Diamond Therapeutics Inc. today announced the appointment of David Brown , PhD, as vice president, pharmaceutical development.
-
Clinical Catch-Up: May 17-21
5/24/2021
It was another busy week for clinical trial announcement. Here’s a look. -
Black Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations
5/19/2021
Once-daily (QD) dose escalation completed; pharmacokinetic (PK) profile consistent with design principles and preclinical predictions
-
Black Diamond Therapeutics to Host Webcast Presentation of Data From Phase 1 Dose-Escalation Portion of MasterKey-01 Clinical Trial
5/17/2021
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced that it will host a webcast presentation on Wednesday, May 19, 2021 at 6:00 PM ET to discuss pharmacokinetic, safety, and preliminary efficacy data from the Phase 1
-
Black Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update
5/7/2021
Patient enrollment and dosing in the Phase 1/2 clinical trial of BDTX-189 continue to track in line with projections at initiation of the study, with dose-escalation portion on track to complete in first half of 2021; initial Phase 1 clinical pharmacokinetic (PK), safety, and preliminary efficacy data to be presented at American Society of Clinical Oncology (ASCO) Annual Meeting
-
Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical Oncology
4/28/2021
Initial pharmacokinetic (PK), safety, and preliminary efficacy data from Phase 1 dose-escalation portion of MasterKey-01 clinical trial to be presented
-
Black Diamond Therapeutics Announces Preclinical Data Presentations on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting
4/10/2021
Black Diamond Therapeutics, Inc., a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, announced the presentation of preclinical data on BDTX-189 and BDTX-1535 at the American Association for Cancer Research Annual Meeting, taking place April 9-14, 2021.
-
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
3/25/2021
Patient enrollment and dosing in the Phase 1/2 clinical trial of BDTX-189 continue to track in line with projections at initiation of the study, with dose-escalation portion on track to complete in first half of 2021; initiation of safety expansion cohort anticipated in the second quarter of 2021 with start of Phase 2 portion planned for second half of 2021 BDTX-1535, a brain-penetrant MasterKey inhibitor of EGFR mutations for glioblastoma multiforme (GBM) and solid tumors
-
Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting
3/10/2021
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that pre-clinical data on BDTX-189 and BDTX-1535 will be presented as late-breaking poster presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting, taking place April 10-15, 2021.
-
Black Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting BRAF and FGFR at ESMO TAT Virtual Congress 2021
3/2/2021
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced the presentation of pre-clinical data from two programs emerging from the Company’s proprietary MAP platform targeting BRAF and fibroblast growth factor receptor (FGFR) at the European Society of Medical Oncology Targeted Anticancer Therapies